SEC Form SC 13G/A filed by ChemoCentryx Inc. (Amendment)

9/12/22 11:13:14 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CCXI alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 CHEMOCENTRYX INC COMMON STOCK Cusip #16383L106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #16383L106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,554 Item 6: 0 Item 7: 7,734 Item 8: 0 Item 9: 7,734 Item 11: 0.010% Item 12: HC Cusip #16383L106 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 7,734 Item 8: 0 Item 9: 7,734 Item 11: 0.010% Item 12: IN Item 1(a). Name of Issuer: CHEMOCENTRYX INC Item 1(b). Address of Issuer's Principal Executive Offices: 835 INDUSTRIAL ROAD, SUITE 600 SAN CARLOS, CA 94070 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 16383L106 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 7,734 (b) Percent of Class: 0.010% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 7,734 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of CHEMOCENTRYX INC. No one other person's interest in the COMMON STOCK of CHEMOCENTRYX INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. September 9, 2022 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on September 9, 2022, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of CHEMOCENTRYX INC at August 31, 2022. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $CCXI alert in real time by email

Recent Analyst Ratings for

$CCXI

Date	Price Target	Rating	Analyst
8/4/2022	$81.00	Buy	Canaccord Genuity
11/10/2021	$107.00 → $110.00	Strong Buy	Raymond James
10/11/2021	$14.00 → $38.00	Underweight → Neutral	JP Morgan
10/11/2021	$64.00	Mkt Perform → Outperform	SVB Leerink
10/11/2021	$62.00 → $107.00	Outperform → Strong Buy	Raymond James
10/8/2021	$62.00 → $107.00	Outperform → Strong Buy	Raymond James
10/8/2021		Neutral → Overweight	Piper Sandler
7/7/2021	$26.00 → $31.00	Hold → Buy	Stifel

More analyst ratings

SEC Form SC 13G/A filed by ChemoCentryx Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $CCXI

$CCXI SEC Filings

SEC Form 15-12G filed by ChemoCentryx Inc.

SEC Form S-8 POS filed by ChemoCentryx Inc.

SEC Form S-8 POS filed by ChemoCentryx Inc.

$CCXI Press Releases

Fastest customizable press release news feed in the world

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

$CCXI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$CCXI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

SEC Form 4: Jain Rita returned 35,863 shares to the company, closing all direct ownership in the company (tax liability)

SEC Form 4: Edwards Thomas A. returned 143,306 shares to the company, closing all direct ownership in the company to satisfy withholding obligation

SEC Form 4: Herron Jennifer Lyn returned 17,237 shares to the company, closing all direct ownership in the company

Canaccord Genuity resumed coverage on ChemoCentryx with a new price target

Raymond James reiterated coverage on ChemoCentryx with a new price target

ChemoCentryx upgraded by JP Morgan with a new price target

$CCXI Financials

Live finance-specific insights

AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

$CCXI Large Ownership Changes

This live feed shows all institutional transactions in real time.